Citadel Advisors’s NeuroOne Medical Technologies NMTC Stock Holding History

Citadel Advisors’s Portfolio NMTC Stock Details NMTC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$45.7K	Buy	+15,032	New	+$61.4K	﹤0.01%	13164
2026 Q1	–	Sell	-7,382	Closed	-$35.5K	–	13803
2025 Q4	$33.6K	Sell	7,382 -26,998	-79%	-$123K	﹤0.01%	12192
2025 Q3	$183K	Buy	34,380 +22,710	+195%	+$111K	﹤0.01%	11348
2025 Q2	$47.5K	Buy	11,670 +9,985	+593%	+$36.9K	﹤0.01%	11797
2025 Q1	$8.59K	Sell	1,685 -11,949	-88%	-$75.8K	﹤0.01%	13635
2024 Q4	$67.6K	Buy	+13,634	New	+$68K	﹤0.01%	12024
2023 Q1	–	Sell	-6,016	Closed	-$43.3K	–	15223
2022 Q4	$43.3K	Buy	+6,016	New	+$53.8K	﹤0.01%	12304

Other funds holding NMTC

Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Bard Associates Chicago, Illinois $451M AUM 66.6% 1-Year Est. Return

PCM

Perkins Capital Management Wayzata, Minnesota $133M AUM 127.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SCM

Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

EIM

Essex Investment Management Boston, Massachusetts $763M AUM 108.51% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return

Citadel Advisors's NMTC Position: Q2 2026 in Review

Citadel Advisors opened a new position in NeuroOne Medical Technologies (NMTC) in Q2 2026: 15,032 shares worth $45.7K. The stake represents ﹤0.01% of the portfolio and ranks #13164 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in NMTC as recently as Q4 2025.

Citadel Advisors first reported a position in NMTC in Q4 2022 and has held it in 7 quarters since. The position peaked at $183K in Q3 2025. 27 funds tracked by Wall St. Rank hold NMTC as of Q2 2026.

Citadel Advisors held 15,032 shares of NeuroOne Medical Technologies worth $45.7K as of Q2 2026.
NeuroOne Medical Technologies was a new Citadel Advisors position in Q2 2026.
NeuroOne Medical Technologies made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #13164 holding.
Citadel Advisors first reported a position in NeuroOne Medical Technologies in Q4 2022 and has held it in 7 quarters since.
Citadel Advisors's NeuroOne Medical Technologies position peaked at $183K in Q3 2025.
27 funds tracked by Wall St. Rank held NeuroOne Medical Technologies as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.